# Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

> **NCT01394939** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jennerex Biotherapeutics** · enrollment: 52 (actual)

## Conditions studied

- Colorectal Carcinoma
- CRC

## Interventions

- **BIOLOGICAL:** JX-594
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01394939
- **Lead sponsor:** Jennerex Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-06
- **Final completion:** 2015-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394939, "Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01394939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*